Home > Insider Trading > Filing (0001714899-23-000055)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1714899	Denali Therapeutics Inc.	DNLI	Biological Products, (No Disgnostic Substances) (2836)	463872213

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1724311	O. Alexander Schuth	C/O Denali Therapeutics Inc. 161 Oyster Point Blvd. South San Francisco CA 94080	Cofo And Secretary	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-04-12	5,102	$5.28	533,793	No	4	M	Indirect	See footnote
Common Stock	Disposition	2023-04-12	5,102	$25.04	528,691	No	4	S	Indirect	See footnote
Common Stock	Acquisiton	2023-04-13	4,898	$5.28	533,589	No	4	M	Indirect	See footnote
Common Stock	Disposition	2023-04-13	4,898	$25.04	528,691	No	4	S	Indirect	See footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Indirect	See footnote
No	4	S	Indirect	See footnote
No	4	M	Indirect	See footnote
No	4	S	Indirect	See footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2023-04-12	5,102	$0.00	5,102	$5.28
Common Stock	Stock Option (right to buy)	Disposition	2023-04-13	4,898	$0.00	4,898	$5.28

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
93,835		2027-03-07	No	4	M	Direct
88,937		2027-03-07	No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	130,792	Direct

Footnotes

Exercised shares were issued to the Schuth Family Trust.
The shares are held of record by The Schuth Family Trust U/A DTD 06/05/2017, for which the Reporting Person serves as trustee.
The sales reported by the Reporting Person were affected pursuant to a Rule 10b5-1 trading plan adopted September 30, 2022.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.49 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $25.00 to $25.10 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Includes 119,156 RSUs.
25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vested monthly thereafter.